Federation Des Caisses Desjardins Du Quebec Summit Therapeutics Inc. Transaction History
Federation Des Caisses Desjardins Du Quebec
- $23.7 Billion
- Q3 2025
A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 9,303 shares of SMMT stock, worth $169,686. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,303Holding current value
$169,686% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
260Shares Held
92.7MCall Options Held
4.63MPut Options Held
4.03M-
Baker Bros. Advisors LP New York, NY33.7MShares$615 Million5.7% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$204 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$144 Million0.0% of portfolio
-
State Street Corp Boston, MA6.36MShares$116 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.54MShares$82.8 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.67B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...